Interactive Workshops

Workshop A: Elevating Psychiatric Preclinical Models: What’s Next?

Wednesday, November 2 | 09:00am - 12:00pm

Despite rapidly advancing technology the world of psychiatric therapeutics remains challenging to navigate. Reduced predictive value of preclinical models presents a roadblock in meaningful drug development that is yet to be fully addressed. Novel therapeutics are required to affect treatment resistant populations and problematic adverse effects and indications. With more companies investing into pipelines to address this large area of unmet need, there has never been a more important time to address drug translation to optimize the chance of clinical success. Attend this impactful, reflective workshop to:

  • Explore the historical landscape of technologies involved in preclinical development to understand the impacts on clinical study
  • Discuss the gap in in vitro and animal models for psychiatric disorders
  • Review the current research and developments in translational models to anticipate implementation into pipeline work
  • Outline the future of preclinical research and opportunities for academic centers and business start-ups to contribute to the field
  • There is likely to be long-term neuropsychiatric morbidity due to stroke, psychiatric disease and long-COVID

Workshop Leaders:

Eric Szelenyi

Eric Szelenyi
Washington Research Foundation
Postdoctoral Fellow
University of Washington

Emily Newman

Emily Newman
Postdoctoral Research  Fellow
Harvard Medical School


Madelyn Ray
Postdoctoral Research Fellow
Boston University School of Medicine

PhD Candidate, Translational Cognitive Neuroscience Lab Western University

Tyler Dexter
PhD Candidate, Translational Cognitive Neuroscience Lab
Western University